aTYR PHARMA INC Investing Cash Flow
aTYR PHARMA INC (ATYR) reported Investing Cash Flow of $26.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-07
- aTYR PHARMA INC net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $15.32M, a 364.16% increase year-over-year.
- aTYR PHARMA INC net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $11.49M.
- aTYR PHARMA INC net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $16.44M.
- aTYR PHARMA INC net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$20.38M, a 213.55% decline year-over-year.
- aTYR PHARMA INC net cash provided by (used in) investing activities for fiscal 2025 was -$5.05M, a 129.32% decline from fiscal 2024.
- aTYR PHARMA INC net cash provided by (used in) investing activities for fiscal 2024 was $17.23M.
- aTYR PHARMA INC net cash provided by (used in) investing activities for fiscal 2023 was -$20.13M, a 142.60% decline from fiscal 2022.
- aTYR PHARMA INC net cash provided by (used in) investing activities for fiscal 2022 was $47.24M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $26.82M 10-Q · filed 2026-08-07 | $43.26M derived: sum of 3 quarters · filed 2026-08-07 | $22.88M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $11.49M 10-Q · filed 2026-05-15 | $27.94M derived: sum of 2 quarters · filed 2026-05-15 | $7.56M derived: sum of 3 quarters · filed 2026-05-15 | $10.86M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $16.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$3.93M derived: sum of 2 quarters · filed 2026-03-05 | -$633.00K derived: sum of 3 quarters · filed 2026-08-07 | -$5.05M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$20.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$17.08M derived: sum of 2 quarters · filed 2026-08-07 | -$21.50M 10-Q · filed 2025-11-06 | -$27.58M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$1.12M 10-Q · filed 2026-08-07 | -$7.20M derived: sum of 3 quarters · filed 2026-08-07 | $10.74M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$4.42M 10-Q · filed 2026-05-15 | -$10.51M derived: sum of 2 quarters · filed 2026-05-15 | $7.44M derived: sum of 3 quarters · filed 2026-05-15 | $14.17M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $11.86M derived: sum of 2 quarters · filed 2026-03-05 | $18.59M derived: sum of 3 quarters · filed 2026-03-05 | $17.23M 10-K · filed 2026-03-05 |
| 2024-09-30 | $17.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $24.67M derived: sum of 2 quarters · filed 2025-11-06 | $23.32M 10-Q · filed 2025-11-06 | $41.14M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $6.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.37M 10-Q · filed 2025-08-07 | $23.19M derived: sum of 3 quarters · filed 2026-03-05 | $27.57M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | -$1.36M 10-Q · filed 2025-05-07 | $16.46M derived: sum of 2 quarters · filed 2026-03-05 | $20.84M derived: sum of 3 quarters · filed 2026-03-05 | $16.69M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $17.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $22.20M derived: sum of 2 quarters · filed 2026-03-05 | $18.05M derived: sum of 3 quarters · filed 2026-03-05 | -$20.13M 10-K · filed 2026-03-05 |
| 2023-09-30 | $4.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $227.00K derived: sum of 2 quarters · filed 2024-11-07 | -$37.95M 10-Q · filed 2024-11-07 | -$35.95M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$4.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$42.33M 10-Q · filed 2024-08-13 | -$40.33M derived: sum of 3 quarters · filed 2025-03-13 | -$19.68M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$38.17M 10-Q · filed 2024-05-02 | -$36.17M derived: sum of 2 quarters · filed 2025-03-13 | -$15.52M derived: sum of 3 quarters · filed 2025-03-13 | -$5.55M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $22.65M derived: sum of 2 quarters · filed 2025-03-13 | $32.62M derived: sum of 3 quarters · filed 2025-03-13 | $47.24M 10-K · filed 2025-03-13 |
| 2022-09-30 | $20.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $30.62M derived: sum of 2 quarters · filed 2023-11-09 | $45.25M 10-Q · filed 2023-11-09 | -$4.10M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $9.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $24.60M 10-Q · filed 2023-08-09 | -$24.75M derived: sum of 3 quarters · filed 2024-03-14 | -$39.60M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $14.63M 10-Q · filed 2023-05-09 | -$34.72M derived: sum of 2 quarters · filed 2024-03-14 | -$49.57M derived: sum of 3 quarters · filed 2024-03-14 | -$53.55M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$49.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$64.20M derived: sum of 2 quarters · filed 2024-03-14 | -$68.17M derived: sum of 3 quarters · filed 2024-03-14 | -$91.57M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$14.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$18.82M derived: sum of 2 quarters · filed 2022-11-14 | -$42.22M 10-Q · filed 2022-11-14 | -$39.02M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-06-30 | -$3.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$27.37M 10-Q · filed 2022-08-15 | -$24.17M derived: sum of 3 quarters · filed 2023-03-14 | -$22.43M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-03-31 | -$23.39M 10-Q · filed 2022-05-10 | -$20.19M derived: sum of 2 quarters · filed 2023-03-14 | -$18.45M derived: sum of 3 quarters · filed 2023-03-14 | -$27.90M derived: sum of 4 quarters · filed 2023-03-14 |
| 2020-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $4.94M derived: sum of 2 quarters · filed 2023-03-14 | -$4.51M derived: sum of 3 quarters · filed 2023-03-14 | $6.90M 10-K · filed 2023-03-14 |
| 2020-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$7.71M derived: sum of 2 quarters · filed 2021-11-12 | $3.70M 10-Q · filed 2021-11-12 | $2.48M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | -$9.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.96M 10-Q · filed 2021-08-11 | $737.00K derived: sum of 3 quarters · filed 2022-03-15 | $7.95M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $11.41M 10-Q · filed 2021-05-14 | $10.19M derived: sum of 2 quarters · filed 2022-03-15 | $17.39M derived: sum of 3 quarters · filed 2022-03-15 | $19.69M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | -$1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $5.99M derived: sum of 2 quarters · filed 2022-03-15 | $8.28M derived: sum of 3 quarters · filed 2022-03-15 | $4.92M 10-K · filed 2022-03-15 |
| 2019-09-30 | $7.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $9.50M derived: sum of 2 quarters · filed 2020-11-13 | $6.14M 10-Q · filed 2020-11-13 | $4.01M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$1.06M 10-Q · filed 2020-08-13 | -$3.20M derived: sum of 3 quarters · filed 2021-03-24 | $17.53M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-03-31 | -$3.35M 10-Q · filed 2020-05-12 | -$5.49M derived: sum of 2 quarters · filed 2021-03-24 | $15.24M derived: sum of 3 quarters · filed 2021-03-24 | $22.40M derived: sum of 4 quarters · filed 2021-03-24 |
| 2018-12-31 | -$2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $18.60M derived: sum of 2 quarters · filed 2021-03-24 | $25.76M derived: sum of 3 quarters · filed 2021-03-24 | $37.17M 10-K · filed 2021-03-24 |
| 2018-09-30 | $20.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $27.89M derived: sum of 2 quarters · filed 2019-11-14 | $39.30M 10-Q · filed 2019-11-14 | $35.77M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $7.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $18.58M 10-Q · filed 2019-08-14 | $15.05M derived: sum of 3 quarters · filed 2020-03-26 | -$24.71M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | $11.41M 10-Q · filed 2019-05-14 | $7.88M derived: sum of 2 quarters · filed 2020-03-26 | -$31.87M derived: sum of 3 quarters · filed 2020-03-26 | |
| 2017-12-31 | -$3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$43.29M derived: sum of 2 quarters · filed 2020-03-26 | -$27.64M 10-K · filed 2020-03-26 | |
| 2017-09-30 | -$39.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$24.11M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $15.65M 10-Q · filed 2018-08-14 | |||
| 2016-12-31 | $33.53M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |